Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them. Send request. ×

Active ingredient:

LEVETIRACETAM 250 MG

Available from:

TEVA PHARMACEUTICAL INDUST.LTD

ATC code:

N03AX14

Pharmaceutical form:

TABLETS

Administration route:

PER OS

Manufactured by:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Therapeutic group:

LEVETIRACETAM

Therapeutic indications:

- Levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - Levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.- Levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patient from 16 years of age with newly diagnosed epilepsy.- Levetiracetam is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Authorization number:

141433195800

Authorization date:

2009-09-01